Understanding the Mutations of SARS-CoV-2
January 11, 2024

A research team in the Department of Pharmaceutical Sciences (PSC) at the University of Maryland School of Pharmacy (UMSOP) is investigating the science behind SARS-CoV-2, the virus that causes COVID-19, and therapeutics to treat it.
A new publication in the Journal of Chemical Information and Modeling, led by Jana Shen, PhD, professor of PSC and co-director of the Computer-Aided Drug Design Center, looks at nirmatrelvir, better known by its trade name Paxlovid, an antiviral drug approved by the US Food and Drug Administration (FDA) to treat mild-to-moderate COVID-19.
Read the full story on the School of Pharmacy's News Center.